Cargando…

Effectiveness of Natalizumab in Achieving No Evidence of Disease Activity (NEDA-3)—Data From a Local Norwegian Cohort

Objective: We aimed to determine the effectiveness of natalizumab (NTZ) by assessing overall No Evidence of Disease Activity 3 (NEDA-3) in a local Norwegian cohort. Background: NTZ is an immunomodulating drug used in the treatment of multiple sclerosis (MS). It has typically been used as a second-li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jaklin, Andreas K., Benjaminsen, Espen, Alstadhaug, Karl B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563783/ https://www.ncbi.nlm.nih.gov/pubmed/34744991 http://dx.doi.org/10.3389/fneur.2021.765837

Ejemplares similares

Rebaseline no evidence of disease activity (NEDA-3) as a predictor of long-term disease course in a Norwegian multiple sclerosis population
por: Simonsen, Cecilia Smith, et al.
Publicado: (2022)

Validation of the multiple sclerosis diagnosis in the Norwegian Patient Registry
por: Benjaminsen, Espen, et al.
Publicado: (2019)

Synesthesia and Migraine: Case Report
por: Alstadhaug, Karl B, et al.
Publicado: (2010)

NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis
por: Puthenparampil, Marco, et al.
Publicado: (2018)

Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod
por: Diem, Lara, et al.
Publicado: (2018)

Thalamic Atrophy Without Whole Brain Atrophy Is Associated With Absence of 2-Year NEDA in Multiple Sclerosis
por: Hänninen, Katariina, et al.
Publicado: (2019)

Increased Within-Network Functional Connectivity May Predict NEDA Status in Fingolimod-Treated MS Patients
por: Piervincenzi, Claudia, et al.
Publicado: (2021)

Multiple sclerosis in the far north - incidence and prevalence in Nordland County, Norway, 1970–2010
por: Benjaminsen, Espen, et al.
Publicado: (2014)

Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years
por: Guerra, Tommaso, et al.
Publicado: (2021)

NEDA—NEutron Detector Array
por: Valiente-Dobón, J J, et al.
Publicado: (2019)

Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3: A Systematic Review and Meta-analysis
por: Rotstein, Dalia, et al.
Publicado: (2022)

Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses
por: Serra López-Matencio, Jose M., et al.
Publicado: (2021)

Caffeine and Primary (Migraine) Headaches—Friend or Foe?
por: Alstadhaug, Karl B., et al.
Publicado: (2019)

No Evidence of Disease Activity (NEDA) in Multiple Sclerosis - Shifting the Goal Posts
por: Pandit, Lekha
Publicado: (2019)

Patient satisfaction with conventional, complementary, and alternative treatment for cluster headache in a Norwegian cohort
por: Bekkelund, Svein I., et al.
Publicado: (2014)

Real-World Effectiveness of Natalizumab in Korean Patients With Multiple Sclerosis
por: Kim, Ki Hoon, et al.
Publicado: (2021)

Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis
por: Proschmann, Undine, et al.
Publicado: (2021)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab
por: Toboso, Inmaculada, et al.
Publicado: (2020)

Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis
por: Prosperini, Luca, et al.
Publicado: (2021)

Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up
por: Kaufmann, Maxi, et al.
Publicado: (2018)

Evidence of disease control: a realistic concept beyond NEDA in the treatment of multiple sclerosis
por: Londoño, Ana C., et al.
Publicado: (2017)

VEP Score of a Left Eye Had Predictive Values for Achieving NEDA-3 over Ten Years in Patients with Multiple Sclerosis
por: Miletic-Drakulic, Svetlana, et al.
Publicado: (2022)

Sudden Caffeine Withdrawal Triggers Migraine—A Randomized Controlled Trial
por: Alstadhaug, Karl B., et al.
Publicado: (2020)

Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study
por: Amato, Maria Pia, et al.
Publicado: (2023)

Physical activity and mortality among Norwegian women – the Norwegian Women and Cancer Study
por: Borch, Kristin Benjaminsen, et al.
Publicado: (2011)

Pregnancy Outcomes in Patients With Multiple Sclerosis Exposed to Natalizumab—A Retrospective Analysis From the Austrian Multiple Sclerosis Treatment Registry
por: Guger, Michael, et al.
Publicado: (2020)

Alterations of the miR-126-3p/POU2AF1/Spi-B Axis and JCPyV Reactivation in Multiple Sclerosis Patients Receiving Natalizumab
por: Mancuso, Roberta, et al.
Publicado: (2022)

Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center
por: Boziki, Marina, et al.
Publicado: (2021)

Physical activity and blood gene expression profiles: the Norwegian Women and Cancer (NOWAC) Post-genome cohort
por: Olsen, Karina Standahl, et al.
Publicado: (2020)

The Successful Treatment of Severe Trigeminal Neuralgia by a Single Mandibular Nerve Block and Subsequent Natalizumab Administration in a Patient with Multiple Sclerosis
por: Norioka, Ryohei, et al.
Publicado: (2020)

The New Neutron Multiplicity Filter NEDA and Its First Physics Campaign with AGATA
por: Jaworski, G, et al.
Publicado: (2019)

aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis
por: Häußler, Vivien, et al.
Publicado: (2021)

Physical activity before and after breast cancer diagnosis and survival - the Norwegian women and cancer cohort study
por: Borch, Kristin Benjaminsen, et al.
Publicado: (2015)

Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study
por: Butzkueven, Helmut, et al.
Publicado: (2020)

No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review]
por: Newsome, Scott D., et al.
Publicado: (2023)

A Preliminary Study on the Meaning of Inflammatory Indexes in MS: A Neda-Based Approach
por: Bunul, Sena Destan, et al.
Publicado: (2023)

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

Admission Serum Calcium Level and Short-Term Mortality After Acute Ischemic Stroke: A Secondary Analysis Based on a Norwegian Retrospective Cohort
por: Lu, Yuzhao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4j9s8fbg55hak4v5lqaa9p2rmn